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Heart  rate  control
Abstract
Objective:  To  evaluate  the  efficacy  and  safety  of  a  heart  rate  (HR)  reduction  protocol  using
intravenous  esmolol  as  bailout  for  failed  oral  metoprolol  regimens  in patients  undergoing
coronary computed  tomography  angiography  (CCTA)  with  64-slice  multidetector  computed
tomography (64-MDCT).
Methods:  Patients  who  underwent  cardiac  64-MDCT  in a  single  institution  between  2011  and
2014 were  analyzed.  Those  with  HR  above  60  beats  per  minute  (bpm)  on presentation  received
oral metoprolol  (50-200  mg)  at least one  hour  before  CCTA.  Intravenous  esmolol  1-2  mg/kg  was
administered  as a  bolus  whenever  HR  remained  over  65  bpm  just  before  imaging.  The  primary
efficacy endpoint  was  HR  <65  bpm  during  CCTA.  The  primary  safety  endpoint  was  symptomatic
hypotension or  bradycardia  up to  hospital  discharge.
Results:  During  the  study  period  CCTA  was  performed  in  947  cases.  In  86%  of  these,  oral  meto-
prolol was  the  only  medication  required  to  successfully  reduce  HR  <60 bpm.  Esmolol  was  used
in the  remaining  130 patients  (14%).  For  esmolol-treated  patients  mean  baseline  and acquisi-
tion  HR  were  74±14  bpm and  63±9  bpm,  respectively  (p<0.001).  The  target  HR  of  <65  bpm
was achieved  in 82  of the  130 esmolol-treated  patients  (63%).  Considering  the  whole  popula-
tion,  esmolol  use  led  to  a  significant  increase  in  the primary  efficacy  endpoint  from  86%  to
95% (p<0.001).  Esmolol  also  resulted  in a  statistically,  but  not  clinically,  significant  reduction
in systolic  blood  pressure  (144±22  to  115±17 mmHg;  p<0.001).  The  combined  primary  safety
endpoint was  only  observed  in  two  (1.5%)  patients.
Conclusion:  Despite  optimal  use  of  oral  beta-blockers,  14%  of  patients  needed  intravenous
esmolol  for  HR  control.  The  pre-medication  combination  of  oral  metoprolol  and on-demand
administration  of  intravenous  esmolol  was  safe  and  effective  and  enabled  95%  of  patients  to  be
imaged with  HR  below  65  bpm.
© 2016  Sociedade  Portuguesa  de Cardiologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  All  rights
reserved.
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Esmolol  endovenoso  em  regime  bail  out  para  controlo  de  frequência  cardíaca
na  tomografia  computorizada  cardíaca
Resumo
Objetivo:  Avaliar  a  eficácia  e  seguranc¸a de um protocolo  de reduc¸ão  de  frequência  cardíaca
(FC) utilizando  esmolol  endovenoso  após  falência  de metoprolol  oral,  em  doentes  submetidos
a angiografia  coronária  por  tomografia  computorizada  (CCTA)  de 64  cortes.
Métodos: De  2011  a  2014  foram  avaliados  os  indivíduos  submetidos  a  CCTA  num  único  centro.
Os indivíduos  com  FC  >60  bpm  à  admissão  receberam  50-200  mg  de  metoprolol  oral  pelo  menos
uma hora  antes  da  CCTA.  Esmolol  endovenoso  em  bólus  (1-2  mg/kg)  foi  administrado  se  FC
>65 bpm  imediatamente  antes  da  aquisic¸ão  de imagem.  O  endpoint  primário  de  eficácia  foi
FC <65 bpm  durante  a  aquisic¸ão  de  imagem  com  contraste.  O  endpoint  primário  de  seguranc¸a
foi hipotensão  ou bradicardia  sintomática  durante  a  permanência  no hospital.
Resultados:  Foram  efetuadas  947 CCTA  durante  o período  de  estudo.  Em  86%  dos  casos,  meto-
prolol oral  foi  o  único  fármaco  utilizado.  Foi  necessária  a  administrac¸ão  de  esmolol  em  130  (14%)
doentes.  Nos  doentes  que  receberam  esmolol,  a  FC  basal  reduziu  em  média  de 74±14  bpm  para
63±9 bpm  (p<0,001).  O  objetivo  primário  de  FC  <65 bpm  foi  alcanc¸ado  em  82  desses  130 doentes
(63%). Considerando  toda  a  populac¸ão,  o  recurso  a  esmolol  permitiu  um  aumento  significativo
da proporc¸ão  de  CCTA  realizados  com  FC  <65  bpm (86%  para  95%  [p<0,001]).  A administrac¸ão  de
esmolol esteve  associada  a reduc¸ão  estatisticamente,  mas não  clinicamente,  significativa
da pressão  arterial  sistólica  (144±22  para  115±17  mmHg;  p<0,001).  O  endpoint  combinado
de seguranc¸a  foi  observado  em  dois  (1,5%)  dos  doentes.
Conclusão:  Apesar  da  utilizac¸ão  sistemática  de betabloqueante  oral,  14%  dos  casos  necessi-
taram de  esmolol  endovenoso  para  controlo  adequado  de FC.  Pré-medicac¸ão  combinada  de
metoprolol oral  e  esmolol  endovenoso  quando  necessária  foi segura  e  eficaz,  e  permitiu  que
95% dos  doentes  apresentassem  FC  <65 bpm  no momento  da  aquisic¸ão  de imagem.
© 2016  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Todos  os
direitos reservados.
Introduction
Adequate  heart  rate  (HR)  control  is  paramount  for  optimal
cardiac  imaging  using  single-source  64-slice  multidetector
computed  tomography  (64-MSDT).1--5 For these  scanners,
HR  during  image  acquisition  should  be  below  65  beats  per
minute  (bpm)  and  preferably  lower  than 60  bpm  for  optimal
image  quality.6 However,  commonly  used pre-medication
regimens  with  oral  or  intravenous  metoprolol  are  frequently
unsatisfactory.7--9 Side  effects,  including  hypotension  and
bradycardia,  are  also  points  of concern.
Intravenous  esmolol,  due  to its rapid onset  and short  half-
life,  has  been  reported  as  a valuable  option  for  adequate
HR  control,  either  alone  or  in combination  with  oral  beta-
blockers.10--12
The  aim  of  the  present  study  is  to  evaluate  the efficacy
and  safety  of an HR  reduction  protocol  using intravenous
esmolol  as bailout  for  failed  oral  metoprolol  regimens  in




Patients  undergoing  CCTA  in a  tertiary  academic  medi-
cal  center  between  August  2011  and  June 2014  were
analyzed.  Those  presenting  in  sinus  rhythm  and  without  con-
traindications  for  beta-blockers  were  included.  All patients
had  indication  for  coronary  anatomy  assessment.  Nineteen
patients  also  had associated  secondary  indications:  percu-
taneous  aortic  valve  implantation  (two),  paroxysmal  atrial
fibrillation  ablation  (sinus  rhythm  during  CCTA)  (three),
assessment  of  left ventricular  morphology  (two),  evalua-
tion  of  valve  heart disease  (three)  or  ascending  aorta  (two),
and  morphological  studies  for congenital  heart  disease
(seven).
Patient  preparation
Oral metoprolol  was  not  used  for patients  presenting  with
HR  <60  bpm,  who  proceeded  directly  to  the CT  table.  Indi-
viduals  with  baseline  HR  of 60-65  bpm  or  >65 bpm  received
50  mg or  100  mg oral  metoprolol,  respectively.  An  additional
dose  of  100 mg metoprolol  was  administered  one  hour later
if HR  was  still  above  65  bpm.  After  repeated  oral meto-
prolol  administration  another  60  min  interval  was  allowed.
Patients  were  then  moved  to  the CT  table.  After sublingual
nitrate  administration  and  just  after  scouting  or  calcium
score  image  acquisition  (Figure  1),  an  intravenous  (IV)  bolus
of  esmolol  1  or  2 mg/kg  was  administered  if  HR  was  >65
bpm  or  >70  bpm,  respectively.  A second  bolus  of  esmolol
was  administered  1 min later  if HR  remained  above  65  bpm
using  the same  dosage.
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Metoprolol 100 mg PO
(repeated after 1 h
if HR >65 bpm, n=10)
Metoprolol 50 mg PO
(repeated after 1 h
if HR >65 bpm, n=5)
HR on CT table
(after NTG 0.5 mg SL and Calcium Scoring)
Esmolol 1-2 mg/kg ev
n=130
(repeated if necessary, n=26)
CCTA CCTA
<65 bpm >65 bpm
Figure  1  Protocol  flowchart.  CCTA:  cardiac  computed  tomography  angiography;  CT:  computed  tomography;  HR:  heart  rate;
IV: intravenous.
Blood  pressure  and  HR were assessed  at baseline,  in the
CT  room  before  and  after  scanning,  and  before  discharge
until systolic  blood  pressure  (SBP)  was  >100  mmHg  and HR
>50  bpm  or  had  returned  to  baseline.
Scan  protocol  and  image  reconstruction
A  single  scanner  was  used for  all  cases (LightSpeed  VCT
XT,  GE  Healthcare,  Milwaukee,  USA).  First,  unenhanced
prospective  heart  rate-triggered  axial  scanning  of the heart
was  performed  for  calcium  scoring  (slice  thickness  2.5  mm;
voltage  120 kV, tube  current  70  mA;  0.35  s partial rotation)
just  after  sublingual  nitrate  administration.  In  view  of  the
requirement  for  esmolol  administration  (HR on the  CT  table
>65  bpm)  a  conservative  acquisition  approach  was  used and
retrospective  gating  with  dose  modulation  was  selected  for
all  these  patients.  The  contrast-enhanced  scan  was  obtained
using  VisipaqueTM (iodixanol)  320  mg injected  through  a
peripheral  vein  at 5  ml/s  followed  by  a  saline  bolus  chase.
The  scan  parameters  used were  0.625  mm collimation,  rota-
tion  time  350  ms, pitch  adjusted  to  each patient’s  HR, tube
voltage  80-120  mV, and  effective  mA 100-600.
Estimated  effective  radiation  dose  was  calculated  by
applying  a  factor  of 0.014  to  the volumetric  CT  dose.
Calcium  scoring  was  included  in the  total  effective  radi-
ation  dose.  Electrocardiographically  gated  datasets  were
reconstructed  from  40%  to 80%  of  the R-R  cycle  length  in
10%  increments.
Endpoints
The  primary  efficacy  endpoint  was  HR <65  bpm  during  con-
trast  image  acquisition  and  the  secondary  efficacy  endpoint
was  HR  <60  bpm  during  contrast  image  acquisition.
The  primary  safety  endpoint  was  symptomatic  hypoten-
sion  (SBP  <90 mmHg)  or  bradycardia  (heart  rate  <45 bpm)
up  to  hospital  discharge,  while  the  secondary  safety  end-
points  were  SBP <90 mmHg  or  HR  <45 bpm  (with  or without
symptoms)  up  to  hospital  discharge.
Statistical  analysis
The  statistical  analysis  was  performed  using  IBM  SPSS
Statistics  (version  22;  IBM  SPSS,  Chicago,  IL).  Continuous
variables  were expressed  as  mean  ±  standard  deviation
or  median  ±  interquartile  range.  Normality  was  tested  by
the  Kolmogorov-Smirnov  test.  Study  group  characteristics
were  compared  using  the Student’s  t  test  or  the  Wilcoxon-
Mann-Whitney  test  for continuous  variables,  and Pearson’s
chi-square  test  or  Fisher’s  exact  test for categorical  meas-
ures,  as  appropriate.
Document downloaded from http://www.elsevier.es, day 21/09/2017. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.
676  S. Aguiar  Rosa  et al.
Table  1  Clinical  characteristics  of  patients  receiving  and
not receiving  esmolol.
Esmolol  No  esmolol
Age  (years)  60.9±13.8  61.5±13.7
Male  54.0%  52.9%
Weight (kg)  73.9±13.7  75.4±14.3
BMI (kg/m2) 27.40±4.42  23.7±2.7
Hypertension  69.6%  73.5%
Diabetes  27.7%  26.5%
Dyslipidemia  68.6%  66.9%
Current smoker 14.5% 12.5%
Previous  MI 18.7% 12.5%
Previous  PCI 17.9% 14.0%
Previous  CABG  16.9%  8.1%
Previous beta-blockers  55.3%  45.6%
BMI: body mass index; CABG: coronary artery bypass grafting;
MI: myocardial infarction; PCI: percutaneous coronary interven-
tion.
Results
Of the  947  CCTAs  performed  (76% of all  CCTAs  performed  in
the  study  period),  HR  <65  bpm  during  CCTA  acquisition  was
achieved  in 830  cases (86%)  using  the  oral  metoprolol  regi-
men  alone.  Intravenous  esmolol  was  necessary  in the  other
130  patients  (54% male,  mean  age 60.9±13.8  years  and  body
mass  index  27.40±4.42  kg/m2)  (Table  1).  Nearly half  (53%)
of  the  esmolol-treated  patients  had been  pre-medicated
before  admission  with  oral  beta-blockers  in  accordance  with
the  indications  of  the referring  physician.
In about  one  third (35%)  of  esmolol-treated  patients,  HR
on  presentation  was  <60  bpm  and  thus  they  received  no  oral
metoprolol,  but  on  the  CT  table HR  increased  to  >65 bpm
requiring  IV  esmolol  as  per  protocol.  The  remaining  65%
(84  patients)  had  received  in-hospital  oral  metoprolol  (mean
dose  0.69 mg/kg)  according  to  the predefined  study  proto-
col.  The  mean  time  between  first  oral  dose  of  metoprolol
and  intravenous  esmolol  administration  was  82±39  min.  The
mean  esmolol  dose  administered  was  1.54  mg/kg.
Initial  mean  HR  in esmolol-treated  patients  was
74±14  bpm,  which  decreased  to  63±9  bpm  during  CCTA
acquisition  (p<0.001),  corresponding  to  a significant  mean
reduction  in  HR  of 15±13%  (Figure  2). During  CCTA  HR  vari-
ability,  defined  as  (maximum  HR  - minimum  HR)/mean  HR,
was  6.3±7.1  in  esmolol  patients.
HR <65  bpm  was  achieved  in 82  of  the  130  esmolol-
treated  patients  (63%).  Thus,  considering  the entire  CCTA
population,  the combined  metoprolol/esmolol  regimen  led
to  a  significant  increase  in  the primary  efficacy  endpoint,
from  86%  to  95%  (p<0.001)  (Figure  3).
The  secondary  efficacy  endpoint  (HR  <60  bpm)  was
reached  in  47  of  the  130 esmolol  patients  (36%).
Four  of  the esmolol-treated  patients  (3%)  had  minimum
HR  below 45  bpm.  Mean  time  to  HR  recovery  to  >60 bpm  in
these  patients  was  37.8±32.3  min.  During  CCTA,  HR  above
80  bpm  was  observed  in five  (4%)  patients.  Mean  HR at  dis-
charge  was  64±7 bpm  (Figure  2)  in the  esmolol  group.
Esmolol  use  resulted  in a  significant  reduction  in mean
SBP  (143±21  to  115±17 mmHg;  p<0.001).  In 11  patients




















Figure  2  Changes  in  heart  rate  after  esmolol  administration.
HR: heart  rate.
HR <65 bpm during CCTA acquisitio n
817 (86%)
Oral metoprolol regimen  Bailout intrav enous esmolol
899 (95%)
p<0.001
Figure  3  Improvement  in  primary  efficacy  endpoint  (heart
rate <65  bpm)  when  intravenous  esmolol  was  added  to  the
heart rate  reduction  protocol.  CCTA:  cardiac  computed  tomo-
graphy  angiography;  HR:  heart  rate.
at discharge  was  119±18  mmHg  (Figure 4A).  Initial dia-
stolic  blood  pressure  was  80±12  mmHg,  decreasing  to  62±11
mmHg  after  intravenous  esmolol  (p<0.001).  Diastolic  blood
pressure  at discharge  was  69±10  mmHg  (Figure  4B).
The  combined  primary  safety  endpoint  (symptomatic
hypotension  or  symptomatic  bradycardia)  was  only  observed
in  two  patients  (1.5%).  Both  cases  resolved  with  supine
positioning,  intravenous  fluids  and atropine  (1 mg)  admin-
istration,  without  further  complications.
In  esmolol-treated  patients  113  scans  (87%)  were  of  good
image  quality,  10  (8%)  were of  moderate  quality,  and  seven
(5%)  were  of  poor  quality and considered  non-diagnostic.
In the latter  group  HR  during CCTA  was  75±9  bpm  and HR
variability  was  5.3  (42.6).
Retrospective  gating  with  dose  modulation  was  selected
for  all  esmolol-treated  patient  due  to  high  baseline  HR. Mean
estimated  radiation dose  was  9.8±10.6  mSv.
Discussion
HR  while  scanning  should  be less  than  65  bpm  and  ideally  less
than  60  bpm  for  optimal  image  quality  when  a  64-slice  MDCT
scanner  is  to  be used.6 Despite  this  recommendation,  in  2007
an American  survey  showed  that  there  were differences  in
beta-blocker  protocols  and  that  a  cutoff  higher  than 65  bpm
was  used  by  80%  of  centers.13
Metoprolol  is  the  most  common  beta-blocker  agent  used
to  achieve  HR  control  during  CCTA.  However,  due  to  its  low
oral  bioavailability,  variable  metabolism  and  inter-subject
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Figure  4  Changes  in  (A)  systolic  and (B)  diastolic  blood  pressure  after  esmolol  administration.
variability,  the  results  are often  suboptimal.  This  has  led
to  the  use  of  several  alternate  regimens  including  intra-
venous  metoprolol,  other  beta-blockers  such as  atenolol,
ivabradine,  or  calcium  channel  blockers.14,15 Nevertheless
intravenous  metoprolol,  the  most  commonly  used parenteral
beta-blocker,  has  demonstrated  limited  efficacy  in  lowering
HR.
Ivabradine  has  been  suggested  as  an alternative  to  beta-
blockers.  Regimens  of  oral  ivabradine  proved  more  effective
in  reducing  HR  than  oral  metoprolol16 and  an intravenous
protocol  demonstrated  efficacy  and  safety  in patients  ineli-
gible  for  intravenous  beta-blockers.17
Esmolol  may  be  at least as  efficacious  as  intravenous
metoprolol  to achieve  optimal  HR.12 However,  to  our  knowl-
edge  there  are  no  studies  reporting  on  esmolol  use  as  bailout
when  previous  oral HR  regimens  have  failed.
In  our  study  the  oral  metoprolol  regimen  used  enabled
86%  of patients  to  achieve  target  HR  <65 bpm.  This  per-
centage  is  higher  than  described  in previous  studies.  De
Graaf  et  al. demonstrated  optimal  beta-blockade  in  73%  of
CCTA  patients  using  oral  metoprolol.18 Intravenous  meto-
prolol,  also  commonly  used,  again  demonstrated  limited
efficacy  in  lowering  HR.  In a  study  by  Jimenez-Juan  et  al.
only  42%  of  patients  who  did  not  achieve  HR  <60  bpm  with
oral  metoprolol  reached  target  HR  with  additional  intra-
venous  metoprolol.19 These  findings  highlight  the need  for  a
more  effective  protocol  for  HR  control.  In addition,  the  rapid
action  and  short  half-life  of  esmolol  make  it  an attractive
drug  in  this  setting.  Similarly  to  data  reported  by  Degertekin
et  al.,10 in  our  study  bolus  esmolol  produced  HR  below
65  bpm  in  63%  (82/130)  of  patients.  Thus,  the introduction
of  bailout  intravenous  esmolol  enabled  95%  of  the  entire
cohort  to  be  imaged  with  HR  below  65 bpm.  The  mean  HR
reduction  was  11  bpm,  4%  of  patients  were  imaged with
HR  greater  than  80  bpm  and only 5% of  CCTA  exams  were
considered  to  be  non-diagnostic.
Our study  suggests  that despite  an  aggressive  beta-
blocker  strategy,  the risk  of side  effects  was  relatively
small.  Only  1.5%  of  patients  had symptomatic  hypotension
or  bradycardia.  Wang  et  al.  reported  0.4%  incidence  of
adverse  events  in  a Chinese  population  treated  with  intra-
venous  esmolol  only.11 In our  cohort,  however, esmolol  was
used  on  top  of  oral metoprolol  in 64%  of  cases,  which  could
explain  the  higher  incidence  of side  effects.  Contraindica-
tions  for  beta-blockers  are  often  considered  a  limitation  for
CCTA  in  patients  with  relatively  high  HR. Esmolol’s  short
half-life  could  make it useful  for patients  who  cannot  toler-
ate  prolonged  beta-blockade.
We  reported  a higher  effective  radiation  dose than
some  real-world  registries.20 Unlike  these studies,  in  which
both  prospective  and  retrospective  acquisition  protocols  are
reported,  herein  we  report  on  a specific  population  sub-
set  in which only a  retrospective  acquisition  protocol  was
chosen  for  all  patients  (because  of  high  baseline  HR).  Also,
in our  registry  about  15%  of  esmolol-treated  patients  had
secondary  indications  for  scanning,  such  as  study  for  trans-
catheter  aortic  valve  implantation,  in which  the scan  range
is  significantly  greater.
The  introduction  of high  temporal  resolution  (83  ms)
dual-source  CT  in clinical  practice  in 2005  has  enabled  high
image  quality  diagnostic  CCTA  studies  at increased  HR  with
less  dependency  on  HR  lowering  agents.21 However,  the lat-
est  generation  of dual-source  scanners  has  introduced  a new
scan  mode,  prospectively  ECG-triggered  helical  data  acqui-
sition  with  very  high  pitch  values.  The  high  pitch  enables
acquisition  with  very  low  radiation  exposure  (<1  mSv) but
low  and regular  HR  is  critical  for  this  technique.  Conse-
quently,  effective  HR  reduction  strategies  are yet  again
pivotal  if such very  low dose  acquisition  protocols  are to
be  followed.22
Study  limitations
This  is  a  retrospective  study with  inherent  limitations
including  potential  selection  bias.  However,  the HR  control
protocol  was  prospectively  designed  and uniformly  applied
to  all eligible  patients.  Also, this was  a  single-center  expe-
rience  with  a relatively  small sample  of  esmolol-treated
patients.  Larger  multicenter  trials  using placebo  or  intra-
venous  metoprolol  as  active  controls  will  be needed  to
clearly  establish  the role  of  intravenous  esmolol  in  this  set-
ting.
Conclusion
Despite  optimal  use  of  oral metoprolol  for  HR control  before
CCTA,  14%  of  cases  still  required  intravenous  esmolol  for
HR control.  Bailout  administration  of  intravenous  esmolol
on  the CT  table  was  safe and effective  and enabled  95%  of
patients  to  be  imaged with  HR below  65  bpm.
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